[Retracted] Bioinformatic Analysis of PTTG Family and Prognosis and Immune Cell Infiltration in Gastric Cancer

Table 2

Evaluation of the association between PTTG expression and clinical prognosis in gastric cancer using the Kaplan-Meier plotting method and other clinicopathological variables.

Clinicopathological characteristics	PTTG1			PTTG2		PTTG3P
		Overall survival ()
		Hazard ratio	value	Hazard ratio	value	Hazard ratio	value
Sex
Female	244	0.44 (0.29-0.65)		1.64 (1.16-2.33)	0.0049	0.56 (0.39-0.81)	0.0019
Male	566	0.79 (0.64-0.98)	0.032	1.43 (1.15-1.77)	0.001	0.67 (0.53-0.85)
Stage
1	69	0.22 (0.05-0.97)	0.028	3.5 (0.99-12.34)	0.038	0.34 (0.12-0.92)	0.027
2	145	0.53 (0.28-0.98)	0.039	1.6 (0.89-2.9)	0.12	0.43 (0.23-0.78)	0.0044
3	319	0.6 (0.45-0.8)	0.00051	1.4 (1.04-1.86)	0.023	0.68 (0.51-0.9)	0.0075
4	152	0.54 (0.35-0.82)	0.0034	0.75 (0.51-1.11)	0.15	0.64 (0.42-0.98)	0.037
Stage T
2	253	0.61 (0.4-0.93)	0.021	1.43 (0.86-2.39)	0.16	0.52 (0.34-0.8)	0.0022
3	208	0.69 (0.47-0.99)	0.044	1.15 (0.82-1.62)	0.42	0.68 (0.49-0.96)	0.029
4	39	0.44 (1.09-1.03)	0.054	0.7 (0.28-1.79)	0.46	0.63 (0.27-1.49)	0.29
Stage N
0	76	0.25 (0.07-0.84)	0.015	3.87 (1.65-9.08)	0.00083	0.46 (0.2-1.08)	0.068
1	232	0.5 (0.33-0.75)	0.00072	1.45 (0.96-2.18)	0.076	0.46 (0.31-0.7)	0.00021
2	129	0.59 (0.37-0.93)	0.021	0.54 (0.33-0.87)	0.11	1.46 (0.85-2.58)	0.16
3	76	0.49 (0.29-0.85)	0.0094	0.58 (0.32-1.06)	0.071	0.48 (0.27-0.87)	0.013
	437	0.58 (0.45-0.76)		1.14 (0.88-1.48)	0.33	0.55 (0.42-0.73)
Stage M
0	459	0.55 (0.41-0.73)		1.31 (1-1.73)	0.053	0.53 (0.4-0.7)
1	58	0.53 (0.29-0.98)	0.039	0.7 (0.37-1.32)	0.26	0.52 (0.27-1)	0.045
Lauren classification
Intestinal	336	0.55 (0.4-0.76)	0.00024	1.61 (1.17-2.22)	0.0031	0.5 (0.36-0.68)
Diffuse	248	0.63 (0.44-0.9)	0.01	1.33 (0.95-1.88)	0.098	0.6 (0.4-0.89)	0.01
Differentiation
Poor	166	1.75 (1.17-2.63)	0.0057	1.28 (0.85-1.92)	0.23	1.2 (0.8-1.81)	0.37
Moderate	67	0.63 (0.31-1.25)	0.18	0.63 (0.33-1.2)	0.15	0.51 (0.26-0.99)	0.042
High	32	0.57 (0.23-1.43)	0.23	1.55 (0.65-3.69)	0.32	0.31 (0.12-0.8)	0.011
Treatment
Surgery alone	393	0.6 (0.44-0.81)		1.2 (0.9-1.6)	0.21	0.61 (0.46-0.82)	0.00072
5 FU-based adjuvant	157	2.12 (1.4-3.21)	0.00032	1.56 (1.1-2.21)	0.011	1.87 (1.26-2.77)	0.0016
Other adjuvant	80	0.49 (0.2-1.18)	0.11	2.84 (1.09-7.41)	0.025	0.29 (0.07-1.25)	0.076
HER2 status
Positive	424	0.75 (0.56-1.01)	0.053	1.41 (1.06-1.88)	0.016	0.75 (0.57-1)	0.05
Negative	641	0.64 (0.51-0.81)	0.00012	1.59 (1.25-2.01)	0.00011	0.62 (0.49-0.78)